Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). ...
Geza Lakner, Kistarcsa, Hungary
Thomas C. Marbury, Orlando, Florida, United States
Eric J. Lawitz, MD, San Antonio, Texas, United States
Celerion Inc., Lincoln, Nebraska, United States
Om Research LLC, Lancaster, California, United States
Panax Clinical Research, Miami Lakes, Florida, United States
Care Access, Ogden, Utah, United States
Shanghai Tongren Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, Shanghai, China
ProSciento, Chula Vista, California, United States
Catalina Research Institute, Montclair, California, United States